TITLE

Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma

AUTHOR(S)
Hussein, Mohamad A.; Baz, Rachid; Srkalovic, Gordan; Agrawal, Neeraj; Suppiah, Revathi; Hsi, Eric; Andresen, Steven; Karam, Mary Ann; Reed, Janice; Faiman, Beth; Kelly, Megan; Walker, Esteban
PUB. DATE
July 2006
SOURCE
Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p889
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To evaluate the efficacy and safety of adding thalidomide to the pegylated liposomal doxorubicin, vincristine, and decreased-frequency dexamethasone (DVd) regimen for multiple myeloma. PATIENTS AND METHODS: Patients newly diagnosed as having active multiple myeloma and those with relapsed-refractory disease were studied between August 2001 and October 2003. Patients received DVd as previously described. Thalidomide was given at 50 mg/d orally and the dose increased slowly to a maximum of 400 mg/d. At the time of best response, patients received maintenance prednisone, 50 mg orally every other day, and daily thalidomide at the maximum tolerated dose for each patient. The primary end point was the rate of complete responses plus very good partial responses as defined by the European Group for Blood and Marrow Transplantation criteria and the Intergroupe Français du Myélome, respectively. RESULTS: Of 102 eligible patients, 53 were newly diagnosed as having multiple myeloma, and 49 had been previously treated for multiple myeloma. The complete response plus very good partial response rate was 49% and 45%, with an overall response rate of 87% and 90% for patients with newly diagnosed and previously treated multiple myeloma, respectively. Furthermore, better responses were associated with Improved progression-free and overall survival. The most common grade 3 and 4 adverse events were thromboembolic events (25%), peripheral neuropathy (22%), and neutropenia (14%). CONCLUSIONS: The addition of thalidomide to the DVd regimen significantly improves the response rate and quality of responses compared with the DVd regimen alone. This improvement is associated with longer progression-free and overall survival. The rate of observed quality responses Is comparable to responses seen with high-dose therapy.
ACCESSION #
21499908

 

Related Articles

  • Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells. Komina, Oxane; No�ke, Ellen; Maurer, Margarita; Wesierska-Gadek, Jozefa // Journal of Experimental Therapeutics & Oncology;2011, Vol. 9 Issue 1, p27 

    Small molecule inhibitors of cyclin-dependent kinases (CDKs) show high therapeutic potential against rapidly dividing cancers and malignancies, characterized by the accumulation of transformed cells due to deregulation of apoptosis, such as multiple myeloma. In the present study we addressed the...

  • Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. LUDWIG, HEINZ; BEKSAC, MERAL; BLADÉ, JOAN; BOCCADORO, MARIO; CAVENAGH, JAMIE; CAVO, MICHELE; DIMOPOULOS, MELETIOS; DRACH, JOHANNES; EINSELE, HERMANN; FACON, THIERRY; GOLDSCHMIDT, HARTMUT; HAROUSSEAU, JEAN-LUC; HESS, URS; KETTERER, NICOLAS; KROPFF, MARTIN; MENDELEEVA, LARISA; MORGAN, GARETH; PALUMBO, ANTONIO; PLESNER, TORBEN; MIGUEL, JESÚS SAN // Oncologist;Jan2010, Vol. 15 Issue 1, p6 

    The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these...

  • Long QT syndrome and torsade de pointes after anthracycline chemotherapy. Colombo, N.; Civelli, M.; Cardinale, D.; Lamantia, G.; Colombo, A.; De Giacomi, G.; Cipolla, C. // Ecancermedicalscience;2009, Vol. 3, p1 

    The article presents a case study of a 54-year old male who suffered progressive micro-molecular multiple myeloma. Results of the diagnosis done in August 1999 revealed that his myeloma was distributed throughout his bones. Moreover, he undergone three cycles of adriamycin, vincristine,...

  • Multiple Myeloma: New Options, New Challenges. Lacy, Martha Q. // Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p877 

    The article focuses on the development concerning treatment of multiple myeloma. Along with the development is the emergence of new combination regimens in treating the disease. Some of the combination therapies are the pegylated liposomal doxorubicin, vincristine and decreased-frequency...

  • Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Witzens, Mathias; Moehler, Thomas; Neben, Kai; Fruehauf, Stefan; Hartschuh, Wolfgang; Ho, Anthony D.; Goldschmidt, Hartmut // Annals of Hematology;Jul2004, Vol. 83 Issue 7, p467 

    Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases. The most common clinical toxicities of thalidomide are constipation, neuropathy, fatigue, sedation, rash, tremor, and edema. We here...

  • Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Klein, Ulrike; Neben, Kai; Hielscher, Thomas; Heiß, Christiane; Ho, Anthony D.; Goldschmidt, Hartmut // Annals of Hematology;Apr2011, Vol. 90 Issue 4, p429 

    Over the past decade, treatment options for patients with multiple myeloma (MM) have improved substantially, resulting in better response rates and prolonged overall survival (OS). Nevertheless, MM remains a challenging disease, especially if renal insufficiency (RI) or extensive pre-treatment...

  • Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma. Das, Anupam; Sil, Amrita; Mishra, Vivek; Kanti Das, Nilay // Indian Journal of Pharmacology;Sep/Oct2014, Vol. 46 Issue 5, p557 

    Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum,...

  • Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Mohty, B; El-Cheikh, J; Yakoub-Agha, I; Avet-Loiseau, H; Moreau, P; Mohty, M // Leukemia (08876924);Jan2012, Vol. 26 Issue 1, p73 

    Treatment of multiple myeloma has evolved over the last decade, most notably with the introduction of highly effective novel agents. It is now possible to aim for deep disease responses in a greater number of patients in an attempt to prolong remission duration and survival. Initially introduced...

  • Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Kastritis, E.; Zervas, K.; Symeonidis, A.; Terpos, E.; Delimbassi, S.; Anagnostopoulos, N.; Michali, E.; Zomas, A.; Katodritou, E.; Gika, D.; Pouli, A.; Christoulas, D.; Roussou, M.; Kartasis, Z.; Economopoulos, T.; Dimopoulos, M. A. // Leukemia (08876924);Jun2009, Vol. 23 Issue 6, p1152 

    When the novel agents thalidomide, bortezomib and lenalidomide are administered to patients with myeloma in the context of clinical trials, they are associated with a significant improvement in response, progression-free survival and in some studies, overall survival (OS); however, their effect...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics